Assessment of the Efficacy and Tolerability of the Fixed-dose Combination of Bisoprolol/Perindopril

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1909 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-11-14

Study Completion Date

2019-10-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study objective - to assess the efficacy, tolerability and adherence of bisoprolol/perindopril FDC in patients with HT and stable CAD in everyday practice.

Type of the program: multicenter, observational, uncontrolled, open program. The program will involve 480 general practitioners (GPs) and cardiologists from the primary care facilities.Each doctor includes four patients. It is planned to include not less than 1920 patients in total.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Multicenter Prospective Observational Study Evaluating the Management of Heart Failure

NCT05180370

Heart Failure

COMPLETED

Beta-Blocker Continuation Versus Interruption in Heart Failure Worsening

NCT00162565

Heart Failure, Congestive

COMPLETED PHASE4

Telemonitoring Program in the Vulnerable Phase After Hospitalization for Heart Failure

NCT05972746

Heart Failure Acute Heart Failure

UNKNOWN NA

Short Term Outcomes of Primary Percutaneous Coronary Intervention (PCI) Patients Presented with Acute Heart Failure in Assuit University Heart Hospital

NCT06825780

Primary Percutaneous Coronary Intervention

NOT_YET_RECRUITING

Optimized Medico-pharmaceutical Collaboration in the Drug Management of Patients With Heart Failure

NCT03902028

Heart Failure

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Multicenter observational open program. Assessment of the efficacy and tolerability of the fixed-dose combination of bisoprolol/perindopril in patients with arterial hypertension and stable CAD in daily clinical practice (STYLE)

Study objectives and purposes:

Primary endpoints:

* efficacy of bisoprolol/perindopril FDC in patients with HT and stable CAD in everyday practice regarding the BP
* efficacy of bisoprolol/perindopril FDC in patients with HT and stable CAD in everyday practice regarding the angina

Secondary endpoints:

* impact on the quality of life of bisoprolol/perindopril FDC in patients with HT and stable CAD in everyday practice
* adherence to bisoprolol/perindopril FDC therapy in patients with HT and stable CAD in everyday practice The program will involve 480 general practitioners (GPs) and cardiologists from the primary care facilities. Each doctor includes four patients. It is planned to include not less than 1920 patients in total.

Milestones of the program:

FSI - November, 2018 LSLV- January, 2019 Database Lock - February, 2019 Statistic Report- May, 2019 Clinical Study Report- January, 2020

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Arterial Hypertension CHD - Coronary Heart Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

the patients with HT and concomitant stable CAD

bisoprolol/perindopril FDC

Intervention Type DRUG

the first and only single-pill combination of beta-blocker and ACE inhibitor

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

bisoprolol/perindopril FDC

the first and only single-pill combination of beta-blocker and ACE inhibitor

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Stable CAD, defined as stable angina pectoris of class 1-3 by CCS (Canadian Cardiovascular Society) classification;
* Previously or newly diagnosed essential hypertension
* Age 18 to 79 years old;
* Informed consent of the patient for participation in the program;
* Decision of the doctor to prescribe bisoprolol/perindopril FDC before the inclusion in the program in accordance to the instruction for use.

Exclusion Criteria

* Stable angina pectoris, class 4;
* History of myocardial infarction or cerebrovascular event within the past 3 months;
* Unstable angina within the past 6 months;
* Chronic heart failure classes 3-4 (NYHA);
* Type 1 diabetes mellitus or decompensated type 2 diabetes mellitus;
* Any serious decompensated concomitant diseases requiring the regular medical therapy;
* Inability to understand the essence of the program and follow the recommendations;
* Contraindications to beta-blockers or ACE inhibitors using;
* Participation of the patient in other trials in the present time or within 30 days before the start of observational program.

Minimum Eligible Age

18 Years

Maximum Eligible Age

79 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No